CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
CSPC Innovation Pharmaceutical Co Ltd
Goodwill
CSPC Innovation Pharmaceutical Co Ltd
Goodwill Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Goodwill | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Goodwill
¥300.8m
|
CAGR 3-Years
32%
|
CAGR 5-Years
56%
|
CAGR 10-Years
37%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Goodwill
¥3.6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
CSPC Innovation Pharmaceutical Co Ltd
Glance View
Nestled in the dynamic landscape of the pharmaceutical industry, CSPC Innovation Pharmaceutical Co Ltd stands as a beacon of innovation and ambition. Evolving from its roots in traditional pharmaceutical practices, the company has carved out a niche for itself by embracing cutting-edge research and development methodologies. At the core of their operations is an unwavering commitment to creating novel drugs that target complex medical challenges. This commitment is propelled by their significant investment in state-of-the-art R&D facilities and collaborations with leading academic institutions and biotech firms. By fostering a rich pipeline of new drugs, CSPC Innovation strives to maintain its competitive edge in a rapidly changing market, driven by both pressing healthcare needs and technological advancements. The company leverages its robust distribution network to bring these innovations to market, drawing upon a diverse portfolio that includes drugs for therapeutic areas such as oncology, cardiovascular health, and metabolic disorders. Revenue generation, therefore, hinges largely on the successful commercialization of these pharmaceutical products, through both direct sales and strategic partnerships. Additionally, CSPC Innovation engages in manufacturing and selling Active Pharmaceutical Ingredients (APIs), further diversifying its income streams. By balancing risk and opportunity, the company not only aims to meet the immediate health demands of its consumer base but also positions itself to capture long-term growth within the global healthcare sector, ensuring a steady influx of revenue and sustainability for future endeavors.